tetano
Editor, Senior Moderator
Clin Transl Med. 2016 Dec;5(1):37. doi: 10.1186/s40169-016-0118-1. Epub 2016 Sep 5.
[h=1]Pharmacokinetics of oseltamivir in infants under the age of 1 year.[/h] Dixit R[SUP]1,[/SUP][SUP]2[/SUP], Matthews S[SUP]3[/SUP], Khandaker G[SUP]4[/SUP], Walker K[SUP]4,[/SUP][SUP]3[/SUP], Festa M[SUP]4,[/SUP][SUP]3[/SUP], Booy R[SUP]4,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Oseltamivir is the only antiviral treatment recommended for influenza in young children over the age of 1 year. There is scant data on oseltamivir pharmacokinetics (PK) in infants <1 year. We set out to perform PK measurements in infants who received oseltamivir.
[h=4]METHODS:[/h] This study was a prospective, uncontrolled, open label evaluation of the pharmacokinetics of oseltamivir metabolism, safety of oseltamivir, viral clearance in infants <12 months diagnosed with influenza by nasopharyngeal influenza nucleic acid antigen test (NAAT). Blood levels of the prodrug oseltamivir and its active carboxylate were measured prior to a dose of oseltamivir and at 4 time points afterwards, to calculate Cmax (ng/mL), Tmax (h), AUC0-t (ng h/mL) and time for AUC (h).
[h=4]RESULTS:[/h] Four children with influenza A received oral oseltamivir, 2.35-3 mg/kg/dose. This dose range produced a target oseltamivir carboxylate plasma concentration in excess of the proposed 12-h target AUC of 3800 ng h/mL, selected from earlier studies to avert resistance. One patient developed GIT adverse event: dry retching.
[h=4]CONCLUSION:[/h] Oseltamivir was well tolerated at a dose of 2.35-3 mg/kg/dose twice a day in infants under the age of 1 year. In general agreement with earlier data, these doses produced a target oseltamivir carboxylate plasma exposure in excess of the proposed 12-h target exposure of AUC equal to 3800 ng h/mL in two patients. The limited plasma concentration data in the remaining two patients were not inconsistent with the target exposure being reached.
[h=4]KEYWORDS:[/h] Infants; Influenza; Oseltamivir; Paediatrics
PMID: 27596232 DOI: 10.1186/s40169-016-0118-1
[PubMed]
[h=1]Pharmacokinetics of oseltamivir in infants under the age of 1 year.[/h] Dixit R[SUP]1,[/SUP][SUP]2[/SUP], Matthews S[SUP]3[/SUP], Khandaker G[SUP]4[/SUP], Walker K[SUP]4,[/SUP][SUP]3[/SUP], Festa M[SUP]4,[/SUP][SUP]3[/SUP], Booy R[SUP]4,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Oseltamivir is the only antiviral treatment recommended for influenza in young children over the age of 1 year. There is scant data on oseltamivir pharmacokinetics (PK) in infants <1 year. We set out to perform PK measurements in infants who received oseltamivir.
[h=4]METHODS:[/h] This study was a prospective, uncontrolled, open label evaluation of the pharmacokinetics of oseltamivir metabolism, safety of oseltamivir, viral clearance in infants <12 months diagnosed with influenza by nasopharyngeal influenza nucleic acid antigen test (NAAT). Blood levels of the prodrug oseltamivir and its active carboxylate were measured prior to a dose of oseltamivir and at 4 time points afterwards, to calculate Cmax (ng/mL), Tmax (h), AUC0-t (ng h/mL) and time for AUC (h).
[h=4]RESULTS:[/h] Four children with influenza A received oral oseltamivir, 2.35-3 mg/kg/dose. This dose range produced a target oseltamivir carboxylate plasma concentration in excess of the proposed 12-h target AUC of 3800 ng h/mL, selected from earlier studies to avert resistance. One patient developed GIT adverse event: dry retching.
[h=4]CONCLUSION:[/h] Oseltamivir was well tolerated at a dose of 2.35-3 mg/kg/dose twice a day in infants under the age of 1 year. In general agreement with earlier data, these doses produced a target oseltamivir carboxylate plasma exposure in excess of the proposed 12-h target exposure of AUC equal to 3800 ng h/mL in two patients. The limited plasma concentration data in the remaining two patients were not inconsistent with the target exposure being reached.
[h=4]KEYWORDS:[/h] Infants; Influenza; Oseltamivir; Paediatrics
PMID: 27596232 DOI: 10.1186/s40169-016-0118-1
[PubMed]